17 apr: FOCUS: Food Processors To Benefit From Cheaper Grain Prices
17 apr: UPDATE: Marathon Oil: Angola's Block 31 To Start Product..
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
19 dec - 
Novo Nordisk: Tresiba får positiv anbefaling om brug ti..
18 dec - 
Novo indgår forskningsaftale med amerikanere - NY
17 dec - 
Bayer indsender FDA-registreringsansøgning for bløderpr..
Relateret debat
22:16 - 
intrinsic...
22:14 - 
læs og forstå intristic value, da det er hvad du spørge..
22:12 - 
Hvad skal jeg med det? :D

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
17 dec
NOVO-B
@ Goodwrench. Jeg ved godt at en aktie falder hvis flere vil ud end ind. Det er selvfølgelig logik. ..
3
14 dec
NOVO-B
Hej Kasper. WACC er et gennemsnit af afkastkravet for virksomhedens gæld og virksomhedens egenkapita..
2
19 dec
NOVO-B
Hvalpepuddel. Dagschartet er ganske entydigt. Kursen har været nede at teste bolligerbåndet(20,2) fo..
1
19 dec
NOVO-B
ALLE mine indlæg læses af ALLE herinde..... fat det nu 
1
19 dec
NOVO-B
ligner bare en enkelt stor odre - måske en pensionskasse der må sælge ud op til årsafslutning mm.  v..
1
19 dec
NOVO-B
Tresiba® receives positive opinion from CHMP for treatment of children with diabetes   Copenhagen, D..
1
16 dec
NOVO-B
Bortset fra det stiger Novo med en halv % på Nasdaq, så den er på vej i den rigtige retning.Novo ska..
1
14 dec
NOVO-B
Hvordan investerer du? Nu har jeg set dig sige at både TA og FA ikke fungerer. 
1
14 dec
NOVO-B
Du googler da bare WACC. Så får du en lang forklaring og angivelse af formler.   Det der er interess..
1

Fondsbørsmeddelelser

Vestas vinder ordre på 34 MW i Tyrkiet - NY

19-12-2014 16:36:45
Vestas har fredag vundet en tyrkisk ordre på levering af 17 vindmøller med en samlet kapacitet på 34 megawatt.Det fremgår af en pressemeddelelse fra den danske ..

Novo Nordisk: Tresiba får positiv anbefaling om brug til børn

19-12-2014 13:26:58
En lægemiddelkomité under de europæiske sundhedsmyndigheder, EMA, anbefaler en udvidet indikation af diabetesmidlet Tresiba.Lægemiddelkomitéen, CHMP, anbefaler,..

Aktier/middag:Carlsberg presset i positivt C20

19-12-2014 11:42:20
Noget tyder på, at julestemningen har smittet af på investorerne på det danske aktiemarked. I hvert fald gør købelysten på det danske C20 Cap-indeks sig gældend..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Novo Nordisk B A/S 266,00 -0,2% Fald i aktiekurs
Novo-Nordisk A/S 43,81 -1,3% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. december 2014 23:16:40
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141211.1 - EUROWEB2 - 2014-12-20 23:16:40 - 2014-12-20 23:16:40 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x